Yahong Pharma completes the C-round financing to accelerate the pace of commercialization

Pharmaceuticals today announced the completion of the C-plus round of financing, the funds raised in addition to supporting the company's existing pipeline products, will also be used to support the commercial preparation of new products. The C-round financing is funded by Tiger Pharma, Boyuan Capital, PCCW Capital and Huayin Gold Investment. Coupled with the C round of financing previously led by Yanyuan Innovation Capital, the two rounds of cumulative financing of 390 million yuan.APL-1202, one of The Key Projects of Yahong Pharmaceuticals, is the world's first innovative drug for the oral treatment of non-muscle immersive bladder cancer, which has been registered for clinical development. As a new anti-tumor mechanism for oral medication, APL-1202 not only avoids urethra damage and pain in bladder perfusion therapy, but also promises to reduce the recurrence of bladder tumors and help patients avoid or delay the fate of full bladder surgery. At present, APL-1202 has completed all patients in China Phase III clinical trials and is ready to enter Phase II clinical trials in the United States.Another product for upcoming Phase III clinical trials, Cevira® is a combination of photodynamic drugs for non-surgical treatment of precanceral cervical lesions. Cevira® will provide women in China and around the world with a new treatment option in addition to surgical treatment, freeing some patients from the pain and side effects of surgical treatment, especially the impact of surgery on future reproductive function.
(
Agency,
)